REMARKS

Claims 54-63 are pending, claims 60-63 being withdrawn.

Sequence Listing

The Examiner has indicated that the sequences in Figure 27 of the application are not followed by a sequence identifier and were not included in the Sequence Listing submitted with the application as filed on April 7, 2004. Applicants respectfully assert that this is incorrect.

As pointed out in Applicants Response to Restriction Requirement dated April 21, 2005, the following documents were submitted with the filing of the above-identified application:

- ❖ Preliminary Amendment under 37 C.F.R. § 1.121 And Submission of Sequence Listing
- Statement to Support Filing and Submission of Sequence Listing In Accordance with 37 C.F.R. § 1.821-1.825
- ❖ Sequence Listing

· A copy of these documents with the postcard indicating receipt of them on April 7, 2004 is enclosed for the convenience of the Examiner.

Applicants Preliminary Amendment amended the description of Figure 27 in the Brief Description of the Drawing to include the sequence identifiers for the two peptides references in the figure. Additionally, as can be seen in the attached Sequence Listing, SEQ ID NO. 2, which corresponds to H-H-H-H-H as used in Figure 27, and SEQ ID NO. 3, which corresponds to R-R-R-R-R as used in Figure 27, were included in the Sequence Listing submitted with the application when filed.

Thus, Applicants assert that the pending application is in compliance with the requirements of 37 C.F.R. §§ 1.821-1.825 and respectfully request that the Examiner acknowledge such compliance.

Election of Invention

The Examiner has issued a restriction requirement alleging that the application claims two distinct inventions. Specifically, the Examiner identifies the two inventions as being:

Group I, consisting of claims 54-59, drawn to a method for identifying a ligand that binds to a protein, classified in Class 436, subclass 89; and

❖ Group II, consisting of claims 60-63, drawn to a computer program product, classified in Class 702, subclass 19.

Pursuant to 37 C.F.R. §1.142, Applicants elect Group I, claims 54-59 without traverse. Claims 60-63 are withdrawn from further consideration by the Examiner under 37 C.F.R. 1.142(b), as being drawn to a non-elected invention. Applicants, however, reserve the right pursuant to 35 U.S.C. §121 to file one or more divisional applications directed to the non-elected invention during the pendency of the present application.

CONCLUSION

Applicants respectfully request prompt examination on the merits of the full scope of claims 54-59. As this response is being filed within the one-month shortened statutory period for reply, no fees are believed to be due in connection with this submission. However, if Applicants are incorrect in this assumption, please charge any fee due to Deposit Account No. 23-2415, referencing Docket No. 30923-702.306.

If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (858) 350-2319.

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Date: <u>July 18, 2005</u>

 650 Page Mill Road Palo Alto, CA 94304 (858) 350-2319 Customer No. 021971 Aubrey Haddach, Reg. No. 48,374

PTO/SB/21 (02-04)


Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Age of 1995. uired to respond to a collection of information unless it displays a valid OMB control number. 10/821,274 Application Number April 7, 2004 Filing Date First Named Inventor Michael W. PANTOLIANO all correspondence after initial filing) Art Unit 1744 David A **Examiner Name** 33 Total Number of Pages in This Submission 30923-702 Attorney Docket Number ENCLOSURES (Check all that apply) After Allowance communication to Fee Transmittal Form Drawing(s) Technology Center (TC) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) Extension of Time Request Terminal Disclaimer (please identify below): 1. Copy of Preliminary Express Abandonment Request Request for Refund Amendment, Submission of Sequence Listing, and IDS Information Disclosure Statement filed April 7, 2004 CD, Number of CD(s) 2. Itemized Return Postcard Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY OR AGENT Firm Aubrey A. Haddach, Reg. No. 48,374, WILSON SONSINI GOODRICH & ROSATI Individual name Signature Date April 21, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as Express Mail (Label No. EV 517732768 US) in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below Typed or printed name Michael Boyd

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

April 21, 2005

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Signature



WSGR Reference No. 30923-702.306

JUL 1 8 2005

APR 2 1 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TANKE The Patent Application of:

Applicant:

Michael W. Pantoliano et al.

Serial No.:

10/821,274

Filed:

April 7, 2004

Title: MICROPLATE THERMAL SHIFT ASSAY APPARATUS FOR LIGAND DEVELOPMENT AND MULTI-VARIABLE PROTEIN CHEMISTRY OPTIMIZATION Group Art Unit: 1744

Examiner: David A. Redding

Certificate of Mailing Under C.F.R. §1.8

I hereby certify that this correspondence and all marked attachments are being deposited by Express Mail, Express Mailing Label No.: EV 517732768 US on 21 Apr-05 addressed to: Mail Stop Amendment; Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313

Michael Boyd

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

This is a response to the Office Communication mailed March 21, 2005. No fees are believed to be due in connection with this submission. However, if any fees are required, please charge any fee due to Deposit Account No. 23-2415, Referencing Docket No. 30923-702.306.

Listing of the Claims, reflecting the status of the claims, begins on page 2 of this paper.

Remarks begin on page 5 of this paper.

Conclusion is on page 6 of this paper.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

The following amendments do not constitute an admission regarding the patentability of the amended subject matter and should not be so construed. Applicant reserves the right to pursue the subject matter of the canceled claims in this or any other appropriate patent application.

Listing of Claims:

Claims 1-53. (Cancelled).

- 54. (Previously presented) A method for identifying a ligand that binds to a protein, comprising the steps of:
- (1) receiving unfolding data that indicates thermal unfolding as a function of temperature for a protein incubated with a molecule tested for binding;
- (2) determining an unfolding temperature for the protein in the presence of the molecule from the unfolding data;
- (3) comparing the unfolding temperature midpoint for the protein incubated with the ligand with the unfolding temperature midpoint for the protein in the absence of any molecules tested for binding; and
- (4) determining that the molecule tested for binding binds to the protein when a difference between the unfolding temperature midpoint for the protein in the presence of the molecule and unfolding temperature midpoint for the protein in the absence of any molecules tested for binding exceeds a threshold.
- 55. (Previously presented) The method according to claim 54, wherein step (2) comprises the step of plotting thermal unfolding as a function of temperature for the protein incubated with the molecule, and determining the unfolding temperature midpoint for the protein in the presence of the molecule from the plot.

- 56. (Previously presented) The method according to claim 55, further comprising the steps of:
- (5) receiving data that indicates thermal unfolding as a function of temperature for the protein in the absence of any molecules tested for binding;
- (6) plotting thermal unfolding as a function of temperature for the protein in the absence of any molecules tested for binding; and
- (7) determining the unfolding temperature midpoint for the protein in the absence of any molecules tested for binding from the associated plot.
- 57. (Previously presented) The method according to claim 54, wherein the molecule that binds is a ligand, and further comprising the step of:
 - (5) estimating ligand binding affinity.
- 58. (Previously presented) The method according to claim 57, wherein step (5) comprises the step of estimating the ligand binding affinity at the unfolding temperature midpoint.
- 59. (Previously presented) The method according to claim 54, wherein step (1) comprises the step of receiving fluorescence data.
- 60. (Previously presented) A computer program product comprising a computer useable medium having control logic embodied in said medium, for causing a computer to process thermal unfolding data, said control logic comprising:
- a thermal unfolding data generating routine that causes the computer system to generate thermal unfolding data from fluorescence information received from a plurality of samples;
- a thermal unfolding curve generation routine that causes the computer system to generate thermal curves from the thermal unfolding data; and
- a thermal unfolding curve comparison routine that causes the computer system to compare the thermal unfolding curves.

61. (Previously presented) A computer program product comprising a computer useable medium having control logic embodied in said medium, for causing a computer to process thermal unfolding data, said control logic comprising:

a thermal unfolding data generating routine that causes the computer system to generate thermal unfolding data from fluorescence information received from a plurality of samples;

a thermal midpoint determining routine that causes the computer system to determine the thermal unfolding midpoint temperatures from the thermal unfolding data; and

a thermal midpoint comparison routine that causes the computer system to compare the thermal unfolding midpoint temperatures.

- 62. (Previously presented) The computer program product according to claim 61, wherein said thermal midpoint determining routine comprises a thermal unfolding curve generation routine that causes the computer system to generate thermal curves from the thermal unfolding data and to determine the thermal unfolding temperature midpoints from the curves.
- 63. (Previously presented) The computer program product according to claim 61, wherein said control logic further comprises:

a positioning control routine that causes the computer system to control a positioning system for the plurality of samples.

REMARKS

Claims 54-63 are pending.

With the filing of the above-identified application, Applicants filed the following documents:

- ❖ Preliminary Amendment under 37 C.F.R. § 1.121 And Submission of Sequence Listing
- Statement to Support Filing And Submission Of Sequence Listing In Accordance with 37 C.F.R. § 1.821-1.825.
- ❖ Request to Approve Proposed Drawing Corrections
- ❖ Information Disclosure Statement and Form PTO-1449

A copy of these documents with the postcard indicating receipt of them on April 7, 2004 is enclosed for your convenience. Because the April 7th Preliminary Amendment cancelled claims 1-53 and added new claims 54-63, Applicants respectfully assert that the Restriction Requirement is improper with respect to the pending claims.

CONCLUSION

Applicants respectfully request prompt examination on the merits of the full scope of claims 54-63. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (858) 350-2319.

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSAT

Date: April 21, 2005

650 Page Mill Road Palo Alto, CA 94304 (858) 350-2319 Customer No. 021971 CLALDALLA CA. WILLULA Aubrey Haddach, Reg. No. 48,374



Other: Statement to Support Filing and Submission of Sequence Listing; Electronic Copy of Sequence Listing; Request to Approve Proposed Drawing Corrections; Preliminary Amendment and Submission of Sequence Listing: Petur



Mailing Label



	ALADR.
+ (******** ****** ***** ***** ***** ***** ****	Customer Copy Addressee
ZU EPEPEPP 13	EXPRESS MAIL UNITED STATES POSTAL SERVICE • Post Office To Addressee DELIVERY (POSTAL USE ONLY)
ORIGIN (POSTAL USE ONLY) PO (E)Coff) Date Ig: Mo Day Vear Strong Second Postage Mo Day Vear Strong Second Postage Weight PM 2nd Day 3rd Day Weight Int'l Alpha Country Code COD Fee Insurance Fee No Dilivery Acceptance Clerk Initials Total Postage & Fees Weekend Medicity Second Total Postage & Fees Weekend Medicity Second Total Postage & Fees	Delivery Attempt Mo. Day
COUSTOMER USE ONLY INCHINGO OF PAYMENT: Express Mid Corporate Acct. No. FROM: (PLEASE PRINT) PHONE T	Federal Agency Acct. No. or Process Service Acct. No. TO: prease PRINT) PHONE (
AAA STE 044988-0308977 Continuation Application	MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, 4 VA, 22313-1450
PRESS HARD. You are making 3 copies. FOR PICKUP OR TRACKING CALL 1-80	00-222-1811 www.usps.com 三星弱星





FILE COPY

In re the Patent Application of:

Applicant:

Pantoliano et al.

Serial No.:

Not yet assigned

Filed:

April 7, 2004

Title: Microplate Thermal Shift Assay

Apparatus For Ligand Development And Multi-Variable Protein Chemistry

Optimization

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

Certificate of Mailing Under C.F.R. §1.8

I hereby certify that this correspondence and all marked attachments are being deposited by Express Mail, Express, Mailing Label No.: EL 989434393 US on April addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Abigail Rivamonte

PRELIMINARY AMENDMENT UNDER 37 C.F.R. § 1.121 AND SUBMISSION OF SEQUENCE LISTING

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The above-identified application, enclosed herewith, is filed under 37 C.F.R. § 1.53(b) as a continuing (continuation) application during pendency of parent application Serial No. 09/801,676. Prior to examination of this application and before calculations of the fees, Applicants respectfully request the that following amendments be entered:

Amendments to the Specification are reflected on page 2 of this paper.

Amendments to the Drawings are reflected on page 4 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 5 of this paper.

Remarks begin on page 8 of this paper.

Conclusion begins on page 9 of this paper.

Amendment to the Specification:

Please amend the specification in accordance with the following:

Delete the paragraph on page 1, beginning on line 4, and replace it with the following paragraph:

This application is a continuation of co-pending U.S. patent application number 09/801,676, filed March 9, 2001. U.S. patent application number 09/801,676 was filed as a continuation of U.S. patent application number 09/459,996, filed December 14, 1999 (U.S. Patent 6,214,293). U.S. patent application number 09/459,996 was filed as a continuation of 08/853,459, filed May 9, 1997 (U.S. Patent 69,036,920), which claimed priority to U.S. provisional application number 60/017,860, filed May 9, 1996, all of which are incorporated herein by reference in their entireties.

Amend the paragraph on page 17 beginning on line 7, as follows:

Figures 8A and 8B show shows the results of a miniaturized microplate thermal shift assay of approxulate binding to the D(II) domain of human FGF receptor 1.

Amend the first paragraph on page 5 as shown below:

Like calorimetric technologies, spectral technologies have been used to monitor temperature induced protein unfolding (Bouvier, M. et al., Science 265:398-402 (1994); Chavan, A.J. et al., Biochemistry 33:7193-7202 (1994); Morton, A. et al., Biochemistry 1995:8564-8575 (1995)). The calorimetric and spectral thermal shift studies described above all share a common limitation. In each study, only one binding reaction was heated and assayed at a time. The single sample heating and assay configuration, as conventionally performed, has impeded the application of thermal shift technologies to high throughput screening of combinatorial libraries. Thus, there is a need for a thermal shift technology which can be used to screen combinatorial libraries, can be used to identify an drank lead compounds, and is applicable to all receptor proteins.

Amend the paragraph starting on page 70, line 4, and ending on page 70, line 15, as shown below:

Using the computer controlled process DirectedDiversity® (see U.S. Patent Number 5,463,564), scientists at 3-Dimensional Pharmaceuticals, Inc. have generated a combinatorial library of compounds directed at the active site of human α-thrombin. Approximately 400 compounds were synthesized and assayed by a conventional spectrophotometric kinetic assay in which succinyl – Ala-Ala-Pro-Arg-p-nitroanilide (SEQ ID NO:1) (Bachem, King of Prussia, PA) served as the substrate. Five of these compounds, which are characterized by K_i's that span almost four orders of magnitude in binding affinity, were used to test the range and limits of detection of the thermal shift assay. These five proprietary compounds are listed in Table 3, along with the K_i for each respective compound, as measured by the kinetic assay (last column). K_i's for these compounds ranged from 7.7 nM for 3dp-4026 to 20.0 μM for 3dp-3811.

Amend the current version of the paragraph starting on page 19, line 1, and ending on page 19, line 2, to read:

Figure 27 is a schematic diagram of a method of screening biochemical conditions that optimize protein folding. This method employs denatured protein tagged with H-H-H-H-H (SEQ ID NO: 2) or R-R-R-R-R (SEQ ID NO: 3).

Please insert the sequence listing at the end of the application.

Amendments to the Drawings:

Please make the following amendments to the drawings:

Replace FIG. 8 with FIGS. 8A and 8B, as shown in the drawings submitted with the concurrently filed Request to Approve Proposed Drawing Corrections.

Amend FIGS. 25 and 41A as shown in red in the drawings submitted with the concurrently filed Request to Approve Proposed Drawing Corrections.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

The following amendments do not constitute an admission regarding the patentability of the amended subject matter and should not be so construed. Applicant reserves the right to pursue the subject matter of the canceled claims in this or any other appropriate patent application.

Claims 1-53 have been cancelled. Claims 54-63 have been added. These amendments introduce no new matter and their entry is respectfully requested.

Listing of Claims:

Claims 1-53. (Cancelled).

- 54. (New) A method for identifying a ligand that binds to a protein, comprising the steps of:
- (1) receiving unfolding data that indicates thermal unfolding as a function of temperature for a protein incubated with a molecule tested for binding;
- (2) determining an unfolding temperature for the protein in the presence of the molecule from the unfolding data;
- (3) comparing the unfolding temperature midpoint for the protein incubated with the ligand with the unfolding temperature midpoint for the protein in the absence of any molecules tested for binding; and
- (4) determining that the molecule tested for binding binds to the protein when a difference between the unfolding temperature midpoint for the protein in the presence of the molecule and unfolding temperature midpoint for the protein in the absence of any molecules tested for binding exceeds a threshold.
- 55. (New) The method according to claim 54, wherein step (2) comprises the step of plotting thermal unfolding as a function of temperature for the protein incubated with the molecule, and determining the unfolding temperature midpoint for the protein in the presence of the molecule from the plot.

- 56. (New) The method according to claim 55, further comprising the steps of:
- (5) receiving data that indicates thermal unfolding as a function of temperature for the protein in the absence of any molecules tested for binding;
- (6) plotting thermal unfolding as a function of temperature for the protein in the absence of any molecules tested for binding; and
- (7) determining the unfolding temperature midpoint for the protein in the absence of any molecules tested for binding from the associated plot.
- 57. (New) The method according to claim 54, wherein the molecule that binds is a ligand, and further comprising the step of:
 - (5) estimating ligand binding affinity.
- 58. (New) The method according to claim 57, wherein step (5) comprises the step of estimating the ligand binding affinity at the unfolding temperature midpoint.
- 59. (New) The method according to claim 54, wherein step (1) comprises the step of receiving fluorescence data.
- 60. (New) A computer program product comprising a computer useable medium having control logic embodied in said medium, for causing a computer to process thermal unfolding data, said control logic comprising:
- a thermal unfolding data generating routine that causes the computer system to generate thermal unfolding data from fluorescence information received from a plurality of samples;
- a thermal unfolding curve generation routine that causes the computer system to generate thermal curves from the thermal unfolding data; and
- a thermal unfolding curve comparison routine that causes the computer system to compare the thermal unfolding curves.

70058972v1

61. (New) A computer program product comprising a computer useable medium having control logic embodied in said medium, for causing a computer to process thermal unfolding data, said control logic comprising:

a thermal unfolding data generating routine that causes the computer system to generate thermal unfolding data from fluorescence information received from a plurality of samples;

a thermal midpoint determining routine that causes the computer system to determine the

thermal unfolding midpoint temperatures from the thermal unfolding data; and

a thermal midpoint comparison routine that causes the computer system to compare the thermal unfolding midpoint temperatures.

- 62. (New) The computer program product according to claim 61, wherein said thermal midpoint determining routine comprises a thermal unfolding curve generation routine that causes the computer system to generate thermal curves from the thermal unfolding data and to determine the thermal unfolding temperature midpoints from the curves.
- 63. (New) The computer program product according to claim 61, wherein said control logic further comprises:

a positioning control routine that causes the computer system to control a positioning system for the plurality of samples.

REMARKS

This Preliminary Amendment is being submitted with the filing of the above-identified application, and therefore Applicants believe that this response is timely filed, and that no fees are due in connection with this submission. In the event that Applicants are incorrect in their assumption, please charge any fee due in connection with this submission to Deposit Account No. 50-2212, Order Number 044988.030.8977.

Amendments to the Specification

The specification has been amended to direct the entry of the enclosed sequence listing after the claims of the above-identified application and to provide SEQ ID NOs next to the specific sequences. In accordance with 37 C.F.R. § 1.821(e), a computer readable copy of the sequence listing is included herewith. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the sequence listing and the computer readable copy of the sequence listing submitted herewith in the above application are the same.

The amendments to the Specification are made in accordance with similar amendments in the parent case. These amendments introduce no new matter. Thus, Applicants respectfully request that the sequence listing submitted herewith be introduced into the above-identified application.

Amendments to the Drawings

FIG. 8 is replaced with FIGS. 8A and 8B, as shown in the drawings submitted with the concurrently filed Request to Approve Proposed Drawing Corrections. Similar changes were approved by the Examiner in the parent application (Serial No. 09/801,676).

FIGS. 25 and 41A are amended as shown in red in the drawings submitted with the concurrently filed Request to Approve Proposed Drawing Corrections. Specifically, in FIG. 25, a diamond symbol and the text "pH 8/0.1 NaCl" is sought to be added and in FIG. 41A, the legend "Control ANS/No Protein" is sought to be added. Similar amendments were approved by the Examiner in the parent application (Serial No. 09/801,676).

The proposed changes add no new matter to the application. Applicants request that the Examiner approve the proposed corrections. After official communication of such approval, Applicants will make the appropriate corrections and submit revised formal drawings.

Amendments to the Claims

Newly added claims 54-63 are directed to data processing aspects of the present invention.

Support for claims 54-63 can be found throughout the specification, for example, at page 67, 1 through page 69, line 9, and Figures 37, 40, and 42.

Claims 54-63 substantially correspond to claims 54-58, 65, and 67-70 from the parent application (Serial No. 09/801,676). Claims 60-63 substantially correspond to non-elected claims 80-83 from the grandparent application (Serial No. 09/459,996, which issued as U.S. Patent No. 6,214,293).

Newly added claims are believed to introduce no new matter and their entry is respectfully requested.

CONCLUSION

Applicants respectfully request that the proposed amendment be entered and the claims examined on the merits. Early and favorable consideration is requested.

If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

Date: April 7, 2004

Aubrey A. Haldach Registration No. 48,374 PILLSBURY WINTHROP, LLP 11682 El Camino Real, Suite 200 San Diego, California 92130-2092 (858) 847-4189



atent Application of:

Applicant:

Pantoliano et al.

ial No.:

Not yet assigned

April 7, 2004

Title: Microplate Thermal Shift Assay

Apparatus For Ligand Development And Multi-Variable Protein Chemistry

Optimization

Group Art Unit: Not yet assigned

Examiner: Not yet assigned

Certificate of Mailing Under C.F.R. §1.8

I hereby certify that this correspondence and all marked attachments are being deposited by Express Mail, Express Mailing Label No.: EL 989434393 US on April 7, 2004 addressed to: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Abigail Rivamonte

STATEMENT TO SUPPORT FILING AND SUBMISSION OF SEQUENCE LISTING IN ACCORDANCE WITH 37 C.F.R. §1.821-1.825

MAIL STOP PATENT APPLICATION Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby state that the content of the paper and computer readable copies of the Sequence Listing. submitted in accordance with 37 C.F.R. § 1.821(c), (e), (f) and (g), or § 1.825(d) and (b), respectively, are the same.

Respectfully submitted,

Date: April 7, 2004

Aubrey A. Haddach Registration No. 48,374 PILLSBURY WINTHROP, LLP 11682 El Camino Real, Suite 200 San Diego, California 92130-2092 (858) 847-4189



SEQUENCE LISTING



<110> Tantoliano, Michael W.

Bone, Roger F. Rhind, Alexander W. Salemme, Francis R.

<120> Computer Program for Thermal Shift Assay Apparatus for Ligand Development and Multi-Variable Protein Chemistry Optimization

<130> 044988-0308977

<140> To be assigned

<141> Herewith

<150> 60/017,860

<151> 1996-05-09

<150> 09/801,676 <151> 2001-03-09

<160> 3

<170> PatentIn version 3.1

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: arginine-p-nitoranilide

<400> 1

Ala Ala Pro Arg

1

<210> 2

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Six histidine epitope tag of
His6D(II)-FGFR1

<400> 2

His His His His His

1

`

CORM

<210> 3
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: C-terminal sequence of His6D(II)FGFR1

<400> 3
Arg Arg Arg Arg Arg Arg

2